RxDoctor Payments Data

Eugene Larsen, DO

Internal Medicine · Price, UTNPI 1447513221

Payments from drug & device makers

$776in general payments, 2019–2025

Across 46 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$182
  • Merck$105
  • Astellas Pharma US Inc$99
  • Novo Nordisk$60
  • Johnson & Johnson$54
  • Collegium Pharmaceutical, Inc.$38
  • plus $237 from 13 others

What the payments were for

  • Food & beverage$67787%
  • Education$9913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$776 in reported general payments places this provider in the 70th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$218,405
Medicare patients
373
Services billed
3,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban125$117,549
OzempicSemaglutide70$82,268
JanuviaSitagliptin Phosphate69$63,516
EliquisApixaban72$57,218
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$45,260
JardianceEmpagliflozin34$36,179
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$28,239
TrulicityDulaglutide28$26,626
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$26,329
Synjardy XrEmpagliflozin/Metformin Hcl38$24,694
Humalog Kwikpen U-200Insulin Lispro21$18,519
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$15,045
Tresiba Flextouch U-100Insulin Degludec11$13,044
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$11,086
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$10,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$54$117,549125 claims
Novo NordiskOzempic$60$82,26870 claims
Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Trijardy Xr$16$79,17299 claims
MerckJanuvia$105$63,51669 claims
PfizerEliquis$26$57,21872 claims
GSKTrelegy Ellipta$23$45,26053 claims
Lilly USA, LLCTrulicity, Mounjaro$12$37,09139 claims
AstraZenecaBreztri Aerosphere, Symbicort$182$30,99356 claims
NovartisEntresto$16$8,01211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 496 internal medicine providers in Utah.

Other internal medicine in Price

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →